[1] Pugliese N, Ponziani F R, Cerini F, et al. Link between persistent, unexplained gamma-glutamyltransferase elevation and porto-sinusoidal vascular disorder. JHEP Rep, 2024, 6(9): 101150.
[2] Zhang Y, Xiong Q, Zhong Y, et al. Clinical characteristics and natural history of porto-sinusoidal vascular disease: A cohort study of 234 patients in China. Liver Int, 2024, 44(9): 2329-2340.
[3] Magaz M, Giudicelli-Lett H, Abraldes J G, et al. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome. J Hepatol, 2025,82(1):72-83.
[4] Sarin S K, Aggarwal S R. Idiopathic portal hypertension. Digestion, 1998, 59(4): 420-423.
[5] De Gottardi A, Rautou P E, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol, 2019, 4(5): 399-411.
[6] Seo J W, Kim E S, Han M H, et al. Non-cirrhotic portal hypertension related to azathioprine therapy in a patient with Crohn's disease. Intest Res, 2021, 19(2): 247-251.
[7] Puente A, Fortea J I, Del Pozo C, et al. Clinical and genetic factors involved in Porto-sinusoidal vascular disorder after oxaliplatin exposure. Dig Liver Dis, 2024.
[8] Hillaire S, Bonte E, Denninger M H, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut, 2002, 51(2): 275-280.
[9] Koksal A S, Koklu S, Ibis M, et al. Clinical features, serum interleukin-6, and interferon-gamma levels of 34 turkish patients with hepatoportal sclerosis. Dig Dis Sci, 2007, 52(12): 3493-3498.
[10] Kline K, Al Hanayneh M, Bilal M, et al. Portal vein thrombosis leading to pre-sinusoidal non-cirrhotic portal hypertension resulting in decreased synthetic function of the liver. Gastroenterol Hepatol Bed Bench, 2019, 12(2): 174-177.
[11] Schouten J N, Garcia-Pagan J C, Valla D C, et al. Idiopathic noncirrhotic portal hypertension. Hepatology, 2011, 54(3): 1071-1081.
[12] Vilarinho S, Sari S, Yilmaz G, et al. Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension. Hepatology, 2016, 63(6): 1977-1986.
[13] Koot B G, Alders M, Verheij J, et al. A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension. J Hepatol, 2016, 64(4): 974-977.
[14] Warasnhe K, Ozcay F, Aydin H I, et al. A novel mutation in TRMT5 associated with idiopathic non-cirrhotic portal hypertension and hepatopulmonary syndrome: Case report of two siblings. Clin Res Hepatol Gastroenterol, 2022, 46(8): 101928.
[15] Calado R T, Regal J A, Kleiner D E, et al. A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One, 2009, 4(11): e7926.
[16] Ciriaci N, Bertin L, Rautou P E. Genetic predisposition to porto-sinusoidal vascular disorder. Hepatology, 2024.
[17] Coukos A, Saglietti C, Sempoux C, et al. High prevalence of short telomeres in idiopathic porto-sinusoidal vascular disorder. Hepatol Commun, 2024, 8(8).
[18] Olivas P, Perez-Campuzano V, Orts L, et al. Porto-sinusoidal vascular disorder in chronic HBV: A significant coexistence not to be overlooked. JHEP Rep, 2024, 6(3): 100996.
[19] Cerda Reyes E, Gonzalez-Navarro E A, Magaz M, et al. Autoimmune biomarkers in porto-sinusoidal vascular disease: Potential role in its diagnosis and pathophysiology. Liver Int, 2021, 41(9): 2171-2178.
[20] Goel A, Ramakrishna B, Muliyil J, et al. Use of serum vitamin B12 level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis. Dig Dis Sci, 2013, 58(1): 179-187.
[21] Elkrief L, Lazareth M, Chevret S, et al. Liver Stiffness by Transient Elastography to Detect Porto-Sinusoidal Vascular Liver Disease With Portal Hypertension. Hepatology, 2021, 74(1): 364-378.
[22] Magaz M, Giudicelli-Lett H, Nicoara-Farcau O, et al. Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome. Transplantation, 2023, 107(6): 1330-1340.
[23] Ferreira-Silva J, Gaspar R, Liberal R, et al. Splenic-hepatic elastography index is useful in differentiating between porto-sinusoidal vascular disease and cirrhosis in patients with portal hypertension. Dig Liver Dis, 2023, 55(1): 75-80.
[24] Ferreira-Silva J, Gaspar R, Liberal R, et al. Transient splenic elastography predicts high-risk esophageal varices in patients with non-cirrhotic portal hypertension. Scand J Gastroenterol, 2021, 56(12): 1462-1466.
[25] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[26] Gane E, Portmann B, Saxena R, et al. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology, 1994, 20(1 Pt 1): 88-94.
[27] Noronha Ferreira C, Seijo S, Plessier A, et al. Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis. Hepatology, 2016, 63(5): 1640-1650.
[28] Rosemurgy A S, Frohman H A, Teta A F, et al. Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial. J Am Coll Surg, 2012, 214(4): 445-453; discussion 453-445.
[29] Maruyama H, Okugawa H, Kobayashi S, et al. Non-invasive portography: a microbubble-induced three-dimensional sonogram for discriminating idiopathic portal hypertension from cirrhosis. Br J Radiol, 2012, 85(1013): 587-595.
[30] Rikkers L F. Operations for management of esophageal variceal hemorrhage. West J Med, 1982, 136(2): 107-121.
[31] Lv Y, Li K, He C, et al. TIPSS for variceal bleeding in patients with idiopathic non-cirrhotic portal hypertension: comparison with patients who have cirrhosis. Aliment Pharmacol Ther, 2019, 49(7): 926-939.
[32] Shalaby S, Miraglia R, Senzolo M. Transjugular Intrahepatic Portosystemic Shunt in Nonmalignant Noncirrhotic Portal Vein Thrombosis and Portosinusoidal Vascular Disorder. J Clin Med, 2024, 13(5).
[33] Romano M, Giojelli A, Capuano G, et al. Partial splenic embolization in patients with idiopathic portal hypertension. Eur J Radiol, 2004, 49(3): 268-273. |
